3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer (Q36028261)

11 August 2017

3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer (English)

1 reference

11 August 2017

1 reference

1 reference

Coleman RE

1

1 reference

11 August 2017

Rubens RD

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 1987

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

56

1 reference

11 August 2017

4

1 reference

11 August 2017

465-469

1 reference

Role of glucocorticoids in management of malignant hypercalcaemia.

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Cancer hypercalcemia: recent advances in understanding and treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Mechanism of malignant hypercalcaemia in carcinoma of the breast

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

The clinical course of bone metastases from breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Treatment of malignant hypercalcaemia with clodronate

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Pathogenesis of hypercalcaemia of malignancy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Tumor products and the hypercalcemia of malignancy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Tamoxifen-induced hypercalcemia in breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001821

Relation between serum and urinary calcium with particular reference to parathyroid activity

23 September 2018

1 reference

12 December 2020

A simplified procedure for the measurement of total hydroxyproline in urine

1 reference

12 December 2020

Mechanisms of bone destruction in the development of skeletal metastases

1 reference

12 December 2020

Hypercalcaemia--a hospital survey

1 reference

12 December 2020

Comparison of two parenteral diphosphonates in hypercalcemia of malignancy

1 reference

12 December 2020

Assessment of response of bone metastases to systemic treatment in patients with breast cancer

1 reference

12 December 2020

Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia

1 reference

12 December 2020

Urinary hydroxyproline and prognosis in human breast cancer

1 reference

12 December 2020

Effects of diphosphonates in hypercalcaemia due to neoplasia

1 reference

12 December 2020

Albumin as an aid to the interpretation of serum calcium

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1987.225

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

3689664

1 reference